F-star Therapeutics Shares Are Rallying Today - Read Why

• invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ: FSTX) for $7.12 per share.

• The proposed acquisition values F-star at approximately $161 million.

• Just a year ago, F-star priced its IPO at $7.

• F-star's next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharma's existing capabilities and reinforces its global oncology pipeline.

• Four programs are progressing in the clinic, three based on F-star's tetravalent platform and one next-generation STING agonist, with multiple further undisclosed programs in development.

• Leveraging its modular antibody technology, F-star has forged collaborations with major international biopharma companies across a wide range of therapeutic areas, including oncology, immunology, and neurology.

• Related: F-star Shares Rise On Bispecific Antibody Therapeutics Pact With Janssen.

• The invoX and F-star Board of Directors have unanimously approved the transaction. It is expected to close in 2H of 2022.

• invoX, established in 2021 in the U.K., is Sino Biopharma's international expansion platform, focusing on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics.

• Price Action: FSTX shares are up 67.1% at $6.65 during the premarket session on the last check Thursday.

See more from Benzinga

• Rite Aid Shares Jump After Upbeat Annual Guidance

• Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.